Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Clinical trial NCT05287113 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05287113
- Sponsor
- Incyte Biosciences International Sàrl
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-14
- Primary completion
- 2025-03-14
- Enrollment
- 176
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.